Everest Medicines’ etrasimod meets primary endpoint in Phase 3 UC trial

By NS Healthcare Staff Writer

01 Dec 23

In the study, etrasimod treatment produced a clinically meaningful and statistically significant improvement in primary endpoint as well…

PharmaceuticalsClinical trials

Qnovia’s smoking cessation asset QN-01 shows superior pharmacokinetic profile in Phase 1 trial

By NS Healthcare Staff Writer

01 Dec 23

The Phase 1 open-label trial studied the delivery of QN-01 via the RespiRx device for three different nicotine…

PharmaceuticalsClinical trials

Merck’s adult pneumococcal vaccine shows superior immunogenicity in Phase 3 trial

By NS Healthcare Staff Writer

29 Nov 23

V116 is an investigational, 21-valent vaccine, currently in late-stage trial for prevention of invasive pneumococcal disease and pneumococcal…

PharmaceuticalsClinical trials

Regeneron, Sanofi’s Dupixent reduces COPD exacerbations in second Phase 3 trial

By NS Healthcare Staff Writer

28 Nov 23

In the trial, Dupixent reduced moderate or severe acute COPD exacerbations by 34% over 52 weeks and led…

PharmaceuticalsClinical trials

GSK’s Blenrep meets primary endpoint in Phase 3 multiple myeloma trial

By NS Healthcare Staff Writer

28 Nov 23

The drug achieved the primary endpoint of progression-free survival and extended the time to disease progression or death…

PharmaceuticalsClinical trials

GSK announces major step towards sustainability ambitions with advancement of low carbon Ventolin programme to Phase III trials

By NS Healthcare Staff Writer

22 Nov 23

Next-generation propellant technology has the potential to reduce greenhouse gas emissions from Ventolin (salbutamol) inhaler by approximately 90%

PharmaceuticalsClinical trials

AstraZeneca launches new health technology business

By NS Healthcare Staff Writer

21 Nov 23

The new business, Evinova, will provide digital health solutions to pharma, biotech, and clinical research organisations (CROs) to…

PharmaceuticalsClinical trials

AstraZeneca’s Imfinzi with chemoradiotherapy fails to meet PFS endpoint in late stage trial

By NS Healthcare Staff Writer

15 Nov 23

The combination failed to improve progression-free survival (PFS) against CRT alone in NSCLC patients and showed an enhanced…

PharmaceuticalsClinical trials

Xarelto plus Aspirin meets primary endpoints in Phase 3 VOYAGER PAD study

By NS Healthcare Staff Writer

15 Nov 23

The combination of Xarelto and Aspirin consistently lowered major adverse limb events (MALE) and major cardiovascular events (MACE)…

PharmaceuticalsClinical trials

Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program

By NS Healthcare Staff Writer

14 Nov 23

Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI…

PharmaceuticalsClinical trials